Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2003 4
2004 5
2005 1
2006 1
2007 2
2008 2
2010 1
2011 2
2012 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R. Roux C, et al. Osteoporos Int. 2012 Jan;23(1):277-84. doi: 10.1007/s00198-011-1574-5. Epub 2011 Mar 2. Osteoporos Int. 2012. PMID: 21365461
METHODS: This study is a post hoc analysis of a subset of patients participating in three prospective, randomized, placebo-controlled clinical trials, with durations of up to 3 years, which evaluated the efficacy of risedronate in reducing fracture risk: Vertebra …
METHODS: This study is a post hoc analysis of a subset of patients participating in three prospective, randomized, placebo-controlled clinic …
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Reginster J, et al. Osteoporos Int. 2000;11(1):83-91. doi: 10.1007/s001980050010. Osteoporos Int. 2000. PMID: 10663363 Clinical Trial.
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. ...Risedronate 5 mg reduced …
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in th …
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
Kanis JA, Barton IP, Johnell O. Kanis JA, et al. Osteoporos Int. 2005 May;16(5):475-82. doi: 10.1007/s00198-004-1698-y. Epub 2004 Jul 23. Osteoporos Int. 2005. PMID: 15875093 Clinical Trial.
Over 3 years, risedronate reduced the risk of new vertebral fractures by 44% (95% CI, 28% to 56%) compared with placebo. ...Adjustment for age, baseline BMD, and prevalent vertebral fractures on fracture risk gave results similar to the u …
Over 3 years, risedronate reduced the risk of new vertebral fractures by 44% (95% CI, 28% to 56%) compared with placebo …
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ, Naganathan V, Barton I, Grauer A. Seibel MJ, et al. J Bone Miner Res. 2004 Feb;19(2):323-9. doi: 10.1359/JBMR.0301231. Epub 2003 Dec 16. J Bone Miner Res. 2004. PMID: 14969403 Free article. Clinical Trial.
The incidence of vertebral fracture was significantly lower in groups assigned to risedronate compared with placebo. This effect was independent of PBR: in patients with high PBR, the relative risk (RR) of vertebral fracture after 1 year of r …
The incidence of vertebral fracture was significantly lower in groups assigned to risedronate compared with placebo. Th …
Risedronate prevents new vertebral fractures in postmenopausal women at high risk.
Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D. Watts NB, et al. J Clin Endocrinol Metab. 2003 Feb;88(2):542-9. doi: 10.1210/jc.2002-020400. J Clin Endocrinol Metab. 2003. PMID: 12574177 Clinical Trial.
To determine the effect of risedronate on vertebral fracture in high-risk subjects, we pooled data from two randomized, double-blind studies [Vertebral Efficacy with Risedronate Therapy (VERT) Multinational (VERT-MN) and VERT …
To determine the effect of risedronate on vertebral fracture in high-risk subjects, we pooled data from two randomized, …
Efficacy of risedronate on clinical vertebral fractures within six months.
Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D, Songcharoen S, Rizzoli R, Di Munno O, Horlait S, Valent D, Watts NB. Roux C, et al. Curr Med Res Opin. 2004 Apr;20(4):433-9. doi: 10.1185/030079903125003125. Curr Med Res Opin. 2004. PMID: 15119979
RESEARCH DESIGN: This study examined the effects of risedronate treatment on the time course of the reduction in the risk of clinical vertebral fractures (i.e., symptomatic fractures), on the risk of moderate-to-severe radiographic vertebral …
RESEARCH DESIGN: This study examined the effects of risedronate treatment on the time course of the reduction in the risk of clinical …
Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
Siris ES, Simon JA, Barton IP, McClung MR, Grauer A. Siris ES, et al. Osteoporos Int. 2008 May;19(5):681-6. doi: 10.1007/s00198-007-0493-y. Epub 2007 Oct 30. Osteoporos Int. 2008. PMID: 17968610 Free PMC article.
Risedronate reduced the fracture risk by 73% (p = 0.023) in this population of women with low femoral neck bone mass and no prevalent vertebral fractures. ...This analysis reports the effect of risedronate to reduce fragility fracture ris …
Risedronate reduced the fracture risk by 73% (p = 0.023) in this population of women with low femoral neck bone mass and no pr …
Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.
Brandi ML. Brandi ML. Curr Med Res Opin. 2010 Nov;26(11):2553-63. doi: 10.1185/03007995.2010.519658. Epub 2010 Sep 21. Curr Med Res Opin. 2010. PMID: 20858031 Review.
METHODS: A review of the literature to determine pivotal vertebral fracture studies for oral bisphosphonates (ibandronate, risedronate and alendronate), strontium ranelate, and raloxifene and to evaluate vertebral antifracture efficacy over time. ...Th …
METHODS: A review of the literature to determine pivotal vertebral fracture studies for oral bisphosphonates (ibandronate, …
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P. Boonen S, et al. J Am Geriatr Soc. 2004 Nov;52(11):1832-9. doi: 10.1111/j.1532-5415.2004.52506.x. J Am Geriatr Soc. 2004. PMID: 15507059 Clinical Trial.
OBJECTIVES: To determine the efficacy of risedronate in reducing vertebral fracture risk in women aged 80 and older with osteoporosis. ...MEASUREMENTS: Cumulative incidence of new vertebral fractures. RESULTS: After 1 year, the risk of new ve …
OBJECTIVES: To determine the efficacy of risedronate in reducing vertebral fracture risk in women aged 80 and older wit …
16 results